Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer
Lung cancer’s intractability is enhanced by its frequent resistance to (chemo)therapy and often high relapse rates that make it the leading cause of cancer death worldwide. Improvement of therapy efficacy is a crucial issue that might lead to a significant advance in the treatment of lung cancer. On...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Molecular Therapy: Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950329924000304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850129929762504704 |
|---|---|
| author | Giti Esmail Nia Elahe Nikpayam Molood Farrokhi Azam Bolhassani Ralph Meuwissen |
| author_facet | Giti Esmail Nia Elahe Nikpayam Molood Farrokhi Azam Bolhassani Ralph Meuwissen |
| author_sort | Giti Esmail Nia |
| collection | DOAJ |
| description | Lung cancer’s intractability is enhanced by its frequent resistance to (chemo)therapy and often high relapse rates that make it the leading cause of cancer death worldwide. Improvement of therapy efficacy is a crucial issue that might lead to a significant advance in the treatment of lung cancer. Oncolytic viruses are desirable combination partners in the developing field of cancer immunotherapy due to their direct cytotoxic effects and ability to elicit an immune response. Systemic oncolytic virus administration through intravenous injection should ideally lead to the highest efficacy in oncolytic activity. However, this is often hampered by the prevalence of host-specific, anti-viral immune responses. One way to achieve more efficient systemic oncolytic virus delivery is through better protection against neutralization by several components of the host immune system. Carrier cells, which can even have innate tumor tropism, have shown their appropriateness as effective vehicles for systemic oncolytic virus infection through circumventing restrictive features of the immune system and can warrant oncolytic virus delivery to tumors. In this overview, we summarize promising results from studies in which carrier cells have shown their usefulness for improved systemic oncolytic virus delivery and better oncolytic virus therapy against lung cancer. |
| format | Article |
| id | doaj-art-5afb62fadfc04be6ac738d2d20d12f03 |
| institution | OA Journals |
| issn | 2950-3299 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular Therapy: Oncology |
| spelling | doaj-art-5afb62fadfc04be6ac738d2d20d12f032025-08-20T02:32:49ZengElsevierMolecular Therapy: Oncology2950-32992024-03-0132120078810.1016/j.omton.2024.200788Advances in cell-based delivery of oncolytic viruses as therapy for lung cancerGiti Esmail Nia0Elahe Nikpayam1Molood Farrokhi2Azam Bolhassani3Ralph Meuwissen4Faculty of Allied Medicine, Cellular and Molecular Research Centre, Iran University of Medical Science, Tehran, Iran; Department of Basic Oncology, Health Institute of Ege University, Izmir, TurkeyDepartment of Regenerative and Cancer Biology, Albany Medical College, Albany, NY, USABioscience Department, University of Skövde, Skövde, SwedenDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; Corresponding author: Azam Bolhassani, Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.Department of Basic Oncology, Health Institute of Ege University, Izmir, Turkey; Ege University Translational Pulmonary Research Center (EgeSAM), Ege University, Izmir, Turkey; Corresponding author: Ralph Meuwissen, Ege University Translational Respiratory Research Center (EgeSAM), Ege University Campus, 35100 Bornova-Izmir, Turkey.Lung cancer’s intractability is enhanced by its frequent resistance to (chemo)therapy and often high relapse rates that make it the leading cause of cancer death worldwide. Improvement of therapy efficacy is a crucial issue that might lead to a significant advance in the treatment of lung cancer. Oncolytic viruses are desirable combination partners in the developing field of cancer immunotherapy due to their direct cytotoxic effects and ability to elicit an immune response. Systemic oncolytic virus administration through intravenous injection should ideally lead to the highest efficacy in oncolytic activity. However, this is often hampered by the prevalence of host-specific, anti-viral immune responses. One way to achieve more efficient systemic oncolytic virus delivery is through better protection against neutralization by several components of the host immune system. Carrier cells, which can even have innate tumor tropism, have shown their appropriateness as effective vehicles for systemic oncolytic virus infection through circumventing restrictive features of the immune system and can warrant oncolytic virus delivery to tumors. In this overview, we summarize promising results from studies in which carrier cells have shown their usefulness for improved systemic oncolytic virus delivery and better oncolytic virus therapy against lung cancer.http://www.sciencedirect.com/science/article/pii/S2950329924000304lung canceroncolytic viral therapyantibody neutralizationcell-mediated carriertarget delivery |
| spellingShingle | Giti Esmail Nia Elahe Nikpayam Molood Farrokhi Azam Bolhassani Ralph Meuwissen Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer Molecular Therapy: Oncology lung cancer oncolytic viral therapy antibody neutralization cell-mediated carrier target delivery |
| title | Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer |
| title_full | Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer |
| title_fullStr | Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer |
| title_full_unstemmed | Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer |
| title_short | Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer |
| title_sort | advances in cell based delivery of oncolytic viruses as therapy for lung cancer |
| topic | lung cancer oncolytic viral therapy antibody neutralization cell-mediated carrier target delivery |
| url | http://www.sciencedirect.com/science/article/pii/S2950329924000304 |
| work_keys_str_mv | AT gitiesmailnia advancesincellbaseddeliveryofoncolyticvirusesastherapyforlungcancer AT elahenikpayam advancesincellbaseddeliveryofoncolyticvirusesastherapyforlungcancer AT moloodfarrokhi advancesincellbaseddeliveryofoncolyticvirusesastherapyforlungcancer AT azambolhassani advancesincellbaseddeliveryofoncolyticvirusesastherapyforlungcancer AT ralphmeuwissen advancesincellbaseddeliveryofoncolyticvirusesastherapyforlungcancer |